Introduction
The prevalence of type 2 diabetes is increasing worldwide due to increasing obesity allied to sedentary lifestyle and a general ageing of populations. 1 Diabetic retinopathy, including diabetic macular oedema (DMO), is the most frequent cause of visual loss and blindness in the working-aged segment of the populations of the developed nations. 2 Increases in this primary cause of visual deterioration will, in turn, lead to a substantial rise in the burden of DMO to people with diabetes and healthcare providers alike. 3 It has been estimated that the healthcare cost of managing people with DMO in England, UK, alone was £92 million in 2010. 4 However, since the introduction of anti-VEGF and intravitreal steroid injections, this is likely to have increased. Management of DMO varies according to the degree of macular thickening, 5 with treatment options including laser photocoagulation, anti-VEGF (vascular endothelial growth factor) therapies and intravitreal steroids.
Fluocinolone acetonide (FAc) 190 µg intravitreal implant is a licensed intravitreal steroid injection approved in the UK for the treatment of visual impairment associated with chronic DMO in eyes that have been insufficiently responsive to available therapies. A single FAc 190 µg intravitreal implant provides a sustained release of FAc for up to three years and has been shown to be effective over this period. 6 Therefore, compared with intravitreal anti-VEGF therapies, where the doses can be administered as frequently as every four weeks, the FAc implant may have a significant impact on resource utilisation in busy hospital eye units. Side effects of
FAc included steroid induced cataracts and raised intraocular pressure (IOP).
Like all other healthcare interventions, treatments for DMO need to demonstrate cost-effectiveness. The UK National Institute for Health and Care Excellence (NICE) has confirmed the cost-effectiveness of the FAc implant in eyes with a pseudophakic lens based on data from FAME. 7 A US economic evaluation using the same data from FAME arrived at an incremental cost-effectiveness ratio (ICER) of $38,763 per quality adjusted life year (QALY) gained, based on the assumption that 40% of people would be treated unilaterally. 8 When it was assumed that 100% of people were treated unilaterally, the FAc implant was found to be cost saving (ICER -$10,620 per QALY). 8 The objective of this study was to evaluate healthcare resource use and associated financial costs involved in treating DMO in routine clinical practice both before and after FAc intravitreal implant, using data from the Iluvien Clinical Evidence study in the United Kingdom (ICE-UK). The ICE-UK study was conducted in order to assess the effectiveness of FAc intravitreal implant in clinical practice, where people are likely to have been exposed to first line anti-VEGF prior to initiation of steroid therapy, a reflection of current clinical practice. Since the NICE recommendations, which were based on the combined FAME studies, the treatment paradigm for DMO has changed, necessitating further research to be conducted in people prescribed anti-VEGF as first line therapy. Importantly, the ICE-UK study collected data not only after implant but also in the 12 months prior to implant, bearing in mind that DMO typically involves a gradual deterioration in vision. The availability of such data, which are rarely reported, enabled the estimation of healthcare resource use in the 12 month periods before and after FAc implant.
Methods

Data source
For this retrospective cohort study, data collected for the ICE-UK study were utilised.
In brief, data from patient medical records from 13 participating UK ophthalmology departments were extracted, pseudonymised and combined into a single dataset.
Collected data included patient demographics, medical history, implant data, and data from multi-disciplinary and medication reviews in the 12 months before and after implant. Quantitative data were also generated from medical records and administrative records, together with clinical measurements.
Ethical approval
The lead clinician and Caldicott Guardian at each centre gave written approval for extraction of anonymised data. The study protocol was approved by the head of research governance at the lead clinical centre. This study was conducted in accordance with the Declaration of Helsinki and the UK Data Protection Act.
Subjects
People with type 1 and type 2 diabetes suffering from DMO were treated with FAc intravitreal implant in at least one eye as part of their routine care. In order to ensure that subjects were eligible for a minimum follow-up of 12 
Outcomes
Healthcare resource use and the corresponding financial costs were estimated for each study eye for the 12 month period both prior to and post index date.
Healthcare resources used on the day of FAc implant were regarded as occurring post implant. Unit costs applied to healthcare resources are listed in Table 1 . The cost of outpatient attendances and procedures and inpatient or day case admissions were derived using the costs detailed in the NHS National Tariff for England, UK. 9 Reviews recorded in the dataset were assumed to have been incurred during an outpatient attendance. Outpatient procedures recorded in the dataset comprised: administration of treatments for DMO (anti-VEGF, steroids and macular laser therapy) and ocular coherence tomography (OCT).
Drug costs for treatments for DMO were taken from the current price listed in the NHS Dictionary of Medicines and Devices (dm+d) database. 10 Costs for bevacizumab were not listed in the dm+d database because no licensed formulation of bevacizumab is available in the UK for treatment of DMO. Instead unit costs for this drug were obtained from the Royal Liverpool and Broadgreen University Hospital, manufacturers and suppliers of an unlicensed formulation of bevacizumab.
The costs of inpatient or day case admissions for cataract operations, glaucoma surgery or vitrectomies were taken from the NHS National Tariff for England, UK. 9 Where more than one procedure was carried out on the same date, the NHS HRG4 (Healthcare Resource Group 4) 2014/15 payment grouper 11 was used to determine the most appropriate HRG. Procedures and reviews listed on the same date as an inpatient admission were assumed to have been carried out as part of the inpatient admission. Similarly, where an inpatient or day case procedure was listed for the fellow eye, procedures carried out in the study eye were assumed to have taken place as part of the inpatient or day case admission. Procedures carried out in first eyes treated with the FAc implant were taken into account when determining the cost of procedures carried out in the second treated eye. For example, if a DMO treatment was administered to both the first FAc treated eye and second FAc treated eye on the same date, the cost applied to the first eye included both the cost of administering the drug as part of an outpatient attendance and the drug cost, whereas the cost applied to the second eye comprised the drug cost only.
The class of IOP-lowering therapy prescribed to an individual was documented at the time of review, but no prescription information (e.g. product, dose, quantity or date prescribed) was recorded. The maximum dose of each IOP medication for each recorded class was taken from the British National Formulary and the volume of eye drops required per 28 days, which covers the shelf life of IOP-lowering drops, was calculated based on previously published data [12] [13] [14] or an estimate of 20 drops per ml.
The need for bilateral treatment with the same drug classes was taken into account in the calculation. A cost per day was generated for each IOP-lowering product listed in the Prescription Cost Analysis (PCA) for England 2015. 15 A weighted average cost per class per day was then generated based on the number of items of each product dispensed in the PCA 2015. Where an eye was treated with more than one IOPlowering class at any one time, it was assumed that combination products would have been prescribed where available.
Statistical analysis
Costs were compared before and after index date using the Wilcoxon signed ranks test because healthcare resource use and costs were not normally distributed.
Statistical analyses were carried out using IBM SPSS Statistics version 20. The costs are detailed as their mean value and standard deviation (SD), as per convention.
Results
Patient characteristics at FAc implant
208 people were eligible for inclusion in the study, contributing 233 FAc treated eyes. 208 (89%) eyes were first eyes treated with FAc implant. Mean (SD) age at implant was 68.1 (10.7) years and 62% of people were male. 15% of people had type 1 diabetes and 85% of people had type 2 diabetes (Table 1) .
205 (88%) treated eyes had a pseudophakic lens prior to FAc implant (Table 1) When the drug and administration costs associated with prescribing the FAc implant were included in the cost estimate, the overall healthcare cost was higher in the 12 months following FAc implant (mean £6,919 versus £2,691, p<0.001; Table 3 However, when the cost of FAc implant was included, post-implant cost was higher than the cost prior to implant. The drug and administration cost associated with inserting the FAc implant was £5,680, but, due to its prolonged duration of action, no drug and administration costs for the FAc implant should be incurred in the subsequent three years, only those costs associated with monitoring and managing adverse events. Using data from the ICE-UK study, we have previously reported that 45%, 32% and 21% of FAc treated eyes improved by ≥5, ≥10 and ≥15 ETDRS letters at 12 months post FAc implant, respectively, despite a mean decrease in visual acuity and central foveal thickness in the year prior to FAc implant. 16, 17 In addition to the visual benefits observed over the first 12 months following implant, 16 sustained improvements in visual acuity were observed for up to three years post implant. 6 When the cost of the FAc intravitreal implant was excluded, the reduction in cost observed post implant was largely due to a reduction in the frequency of anti-VEGF therapy and its administration. No significant change in the number of laser treatments administered prior to and post implant was observed and three of the study sites did not allow for anti-VEGF use after FAc implantation. The Diabetic Retinopathy Clinical Research Network reported a steady decrease in the number of ranibizumab injections administered over the trial's five year follow-up period, with no corresponding decrease in visual acuity. 18, 19 In the FAME study, the use of laser and anti-VEGF treatments was more common in the sham (untreated) arm of the study compared with FAc 0.2 µg/day. 6 Conversely, as FAc 190 µg intravitreal implant is only licensed in eyes that have been insufficiently responsive to other therapies, the reduction in the use of anti-VEGF therapies in the 12 months post implant may reflect prior non-response to these agents. Previous insufficient responsiveness to available DMO therapies was not a requirement for selection into the FAME study, however a decrease anti-VEGF therapy was still observed. 6 Intensive intravitreal injection regimens have been previously reported to have an effect on the quality of life of people with DMO. 20 Compared with anti-VEGF therapies, the FAc implant has the advantage of requiring substantially less frequent intravitreal injections, and therefore improved patient compliance, reduced treatment burden and reduced resource use have been previously cited as possible advantages. 21 However, monitoring for complications is recommended two to seven days after insertion of the implant and then at least quarterly thereafter, 22 necessitating regular visits to the ophthalmology outpatient department. However, in this study, a small but significant decrease in the number of outpatient appointments was observed, perhaps owing to the reduction in the number of anti-VEGF intravitreal injections administered. No significant difference in the number of OCT scans carried out was observed prior to and post implant.
Side effects associated with steroids as a class include cataracts and raised IOP.
However, the cost of IOP-lowering medication, monitoring and glaucoma surgery both before and after implant represented a very small segment of the overall cost of DMO care. More cataract operations were recorded prior to FAc implant and most treated eyes had a pseudophakic lens at the time of implant. This is most likely to be due to the NICE recommendation in the UK that the FAc intravitreal implant be used only in eyes with a pseudophakic lens. 7 Yang and colleagues have shown that similar or possibly better outcomes can be achieved in those undergoing cataract surgery following FAc implantation compared with pseudophakic eyes treated with FAc implant. 23 Several studies have reported on the cost-effectiveness of treatments for DMO.
Pershing and colleagues investigated the cost-effectiveness of laser monotherapy or anti-VEGF or triamcinolone alone or in combination with laser therapy in diabetic macular oedema and reported that costs were reduced with all interventions except laser monotherapy; the number of quality-adjusted life years (QALYs) increased for all interventions except for triamcinolone monotherapy. 24 Bevacizumab is cheaper than aflibercept or ranibizumab but remains unlicensed for DMO. However, bevacizumab has been demonstrated to be more cost-effective than aflibercept and ranibizumab in DMO. 25 The FAc intravitreal implant was approved by NICE for the management of DMO in eyes with an artificial lens and licensed for the treatment of DMO that is insufficiently responsive to other available therapies. 7 The NICE Appraisal Committee determined that, in eyes with a pseudophakic lens, the incremental cost-effectiveness ratio (ICER) of FAc was between £17,500 and £30,000
per QALY gained, depending on the utilities used and providing that the FAc implant was supplied under the terms of the patient access scheme. NICE concluded that FAc intravitreal implant in pseudophakic eyes was therefore a cost-effective use of NHS resources. In an economic evaluation of the FAc implant by Moore and colleagues based on the results of the FAME studies, the expected incremental costeffectiveness ratio for treatment with an FAc implant was reported to be $38,763 (approximately £30,800) when 40% of people are treated unilaterally, and costsaving (ICER -$10,620 per QALY) when 100% of people are treated unilaterally. 8 
Strengths and limitations
Advantages and disadvantages of the ICE-UK study have been discussed previously. 16 As this is an observational study, several limitations may occur. Misclassification of outcomes, effectiveness and safety may have occurred, although data were taken from patient notes and electronic medical records. Retrospective studies are subject to confounding and can only be used to infer association and not causation. Duration of DMO at the time of implant was not recorded. It was not possible to determine the individual's exact age or their duration of diabetes at implant because these were recorded at their last clinic visit only, the date of which was not supplied.
Discrepancies between lens status and cataract operations were observed and have been discussed previously. 16 As it was important to determine the date of any intervention or procedure, recorded cataract operations were included in the study but lens changes were not. This may have led to an underestimation of the number and total cost of cataract operations. The recording of procedures occurring near to the end of the study observation period (15 April 2016) may not be complete as it was possible for procedure dates to predate review dates. Analysis was restricted to 12 months follow-up post implant because available follow-up after this date varied from person to person. No cost was applied to IOP-lowering medication when the class prescribed was specified as 'other'.
First and second treated eyes from the same person were analysed as independent observations. However, second eyes may be more likely to be treated with FAc implant if the subject had a positive response to treatment in the first eye. In addition, treatment of the second eye may be more likely to occur at certain treatment centres.
Certain assumptions were made in costing ranibizumab, which is available as both a prefilled syringe and a vial. 14 The prefilled syringe is designed to be used for the treatment of a single eye. The vial is available as a vial plus injection kit, a vial only pack and a vial plus filter needle pack. It was assumed that, for bilateral treatment with the same drug on the same date, different product packs would be used to treat each eye when the same drug was administered bilaterally on the same date.
Another limitation is that ranibizumab, aflibercept and FAc intravitreal preparations indicated for DMO are listed on the NICE Patient Access Scheme list 26 and supplied to the NHS at a discounted rate. In this study, however, the list price of the drug was used, as any price agreements between the manufacturer and the Department of Health under the Patient Access Scheme are not publically available.
Conclusion
The ICE-UK study was designed to investigate the real-world effectiveness of FAc 190 µg intravitreal implant. Various standard clinical outcomes of care for DMO when treated with the FAc implant are reported in this supplement. 16 Most of the study eyes included in the study had been treated with anti-VEGFs prior to FAc implantation, and mean visual acuity in the 12 months prior to FAc implant declined.
Following intravitreal implantation, vision improved on average to a modest extent.
Whilst it improved in some people, it at least stabilised with no further deterioration in the majority of the remaining subjects. During the 12 month follow-up period, 30% of patients were prescribed concomitant treatments for DMO. In this study we report that, following exclusion of the cost of the FAc implant itself, there was a corresponding decrease in healthcare resource usage over this period compared with the 12 months prior to implant. The cost of treating raised intraocular pressure was relatively low. Bearing in mind that this disease process typically involves increasing visual morbidity over time, and that the FAc implant functions for at least three years, it is likely that there will be an overall cost saving over this extended period, as has been reported in a previous economic evaluation. 16 95% CI
